We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

73 hedge funds and large institutions have $192M invested in AEON Biopharma in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

24% more funds holding

Funds holding: 59 → 73 (+14)

12% more capital invested

Capital invested by funds: $172M → $192M (+$20.2M)

0.2% more ownership

Funds ownership: 0.79% → 0.99% (+0.2%)

Holders
73
Holders Change
+14
Holders Change %
+23.73%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
14
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$6.57M
2
KIM
Karpus Investment Management
New York
+$4.51M
3
Millennium Management
Millennium Management
New York
+$3.74M
4
JP Morgan Chase
JP Morgan Chase
New York
+$2.67M
5
PC
Periscope Capital
Ontario, Canada
+$2.5M

Top Sellers

Rank Fund Capital Flow
1
PAMP
Polar Asset Management Partners
Ontario, Canada
-$2.92M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$2.44M
3
WAM
Wolverine Asset Management
Illinois
-$1.72M
4
SC
Sculptor Capital
New York
-$1.46M
5
CL
CSS LLC
Illinois
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECP
1
Empyrean Capital Partners
California
$13.6M – – –
Marshall Wace
2
Marshall Wace
United Kingdom
$12.9M +$6.57M +9,350 +103%
DKCM
3
Davidson Kempner Capital Management
New York
$12.3M – – –
HSBC Holdings
4
HSBC Holdings
United Kingdom
$10.7M +$1.99M +2,834 +23%
Citadel Advisors
5
Citadel Advisors
Florida
$10.7M +$19.7K +28 +0.2%
RCM
6
Radcliffe Capital Management
Pennsylvania
$8.42M – – –
SCM
7
Shaolin Capital Management
Florida
$7.87M – – –
PC
8
Periscope Capital
Ontario, Canada
$7.33M +$2.5M +3,556 +51%
LA
9
Linden Advisors
New York
$5.83M – – –
LP
10
LMR Partners
United Kingdom
$5.83M – – –
Millennium Management
11
Millennium Management
New York
$5.63M +$3.74M +5,316 +195%
Hudson Bay Capital Management
12
Hudson Bay Capital Management
Connecticut
$5.26M -$2.44M -3,473 -32%
UOC
13
UBS O'Connor
Illinois
$4.99M +$135K +192 +3%
FTCM
14
Fir Tree Capital Management
New York
$4.92M +$56.3K +80 +1%
Blackstone Inc
15
Blackstone Inc
New York
$4.86M – – –
CH
16
CVI Holdings
Delaware
$4.86M – – –
TCM
17
Tenor Capital Management
New York
$4.85M – – –
KIM
18
Karpus Investment Management
New York
$4.73M +$4.51M +6,413 +1,848%
PMAM
19
Picton Mahoney Asset Management
Ontario, Canada
$3.4M – – –
WA
20
Whitebox Advisors
Minnesota
$3.13M – – –
Wells Fargo
21
Wells Fargo
California
$2.76M – – –
Goldman Sachs
22
Goldman Sachs
New York
$2.69M – – –
JP Morgan Chase
23
JP Morgan Chase
New York
$2.66M +$2.67M +3,793 New
CCA
24
Castle Creek Arbitrage
Colorado
$2.48M – – –
SCC
25
Spring Creek Capital
Kansas
$2.43M – – –
1
2 3 4

AEON Hedge Fund Activity: Q4 2021 in Review

73 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q4 2021, worth a combined $192M — up 12% from $172M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new AEON positions and 4 closed out — a net gain of 14 holders — while 14 added to existing stakes and 6 trimmed.

The largest buyer was Marshall Wace, adding an estimated $6.57M. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $2.92M sold.

  • 73 institutional investors held AEON Biopharma (AEON) as of Q4 2021, up from 59 in Q3 2021.
  • Funds reported $192M of AEON Biopharma stock for Q4 2021, up 12% quarter-over-quarter.
  • 18 funds opened new AEON Biopharma positions in Q4 2021 and 4 closed out, a net change of +14 holders.
  • The largest AEON Biopharma buyer in Q4 2021 was Marshall Wace, an estimated $6.57M added.
  • The largest AEON Biopharma seller in Q4 2021 was Polar Asset Management Partners, an estimated $2.92M sold.

Based on aggregated 13F filings for Q4 2021.